Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wal-Mart, Kroger Plan B policies slammed

This article was originally published in The Tan Sheet

Executive Summary

A national reproductive rights group presses the Wal-Mart and Kroger chains to make Plan B emergency contraception available at all their stores regardless of whether employees at the facilities oppose dispensing the drug. NARAL Pro-Choice America is supporting women who were refused access to Plan B at stores where the product was stocked - a Rome, Ga., Kroger in December and a Columbus, Ohio, Wal-Mart in January. While Kroger says it allows operators of individual stores to decide whether to make any product available, Wal-Mart said in March 2006 it would stock Plan B at all of its stores. NARAL says it organized a news conference March 9 in Atlanta to announce a Georgia campaign to raise awareness about EC and ask Kroger and other pharmacies to make Plan B available. The organization also is conducting an online campaign asking for letters "urging [Wal-Mart President and CEO H. Lee Scott Jr.] to improve company policy to require Wal-Mart pharmacies to fulfill requests for Plan B"...

You may also be interested in...



EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel